


PRODUCT INFORMATION



JWH 203 N-(4-hydroxypentyl) metabolite

Item No. 14227

CAS Registry No.: 1843184-38-2
Formal Name: 2-(2-chlorophenyl)-1-[1-(4-hydroxypentyl)-1H-indol-3-yl]-ethanone
MF: C₂₁H₂₂ClNO₂
FW: 355.9
Purity: ≥95%
UV/Vis.: λ_{max}: 212, 246, 305 nm
Supplied as: A solution in methanol
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Description

JWH 203 (Item No. 9000736) is an analgesic chemical from the phenylacetylindole family that acts as a cannabinoid (CB) agonist with K_i values of 8.0 and 7.0 nM at the central (CB₁) and peripheral (CB₂) CB receptors, respectively.¹ Similar to the related 2'-methoxy compound JWH 250 (Item No. 13634), JWH 203 has a phenylacetyl group in place of the naphthoyl ring used in most aminoalkylindole cannabinoid compounds. Compared to JWH 250, JWH 203 displays slightly more potent binding affinities for the CB₁ and CB₂ CB receptors (JWH 250 K_is = 11 and 33 nM, respectively).¹ JWH 203 N-(4-hydroxypentyl) metabolite (Item No. 14227) is expected to be a metabolite of JWH 203 that would be detectable both in serum and in urine. While similar hydroxylated phase I metabolites of synthetic CB retain activity, the physiological properties of this compound have yet to be determined.^{2,3} This product is intended for research and forensic applications.

References

1. Huffman, J.W., Szklennik, P.V., Almond, A., *et al.* 1-Pentyl-3-phenylacetylindoles, a new class of cannabimimetic indoles. *Bioorg. Med. Chem. Lett.* **15**(18), 4110-4113 (2005).
2. Brents, L.K., Reichard, E.E., Zimmerman, M., *et al.* Phase I hydroxylated metabolites of the K2 synthetic cannabinoid JWH-018 retain *in vitro* and *in vivo* cannabinoid 1 receptor affinity and activity. *PLoS One* **6**(7), 1-9 (2011).
3. Brents, L.K., Gallus-Zawala, A., Radomska-Pandya, A., *et al.* Monohydroxylated metabolites of the K2 synthetic cannabinoid JWH-073 retain intermediate to high cannabinoid 1 receptor (CB1R) affinity and exhibit neutral antagonist to partial agonist activity. *Biochem. Pharmacol.* **83**(7), 952-961 (2012).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 06/15/2023

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM